{"id":52751,"date":"2023-01-10T14:02:29","date_gmt":"2023-01-10T13:02:29","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/twist-bioscience-and-centogene-launch-three-panels-to-advance-rare-disease-and-hereditary-cancer-research-and-support-diagnostics\/"},"modified":"2023-01-10T14:02:29","modified_gmt":"2023-01-10T13:02:29","slug":"twist-bioscience-and-centogene-launch-three-panels-to-advance-rare-disease-and-hereditary-cancer-research-and-support-diagnostics","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/twist-bioscience-and-centogene-launch-three-panels-to-advance-rare-disease-and-hereditary-cancer-research-and-support-diagnostics\/","title":{"rendered":"Twist Bioscience and CENTOGENE Launch Three Panels to Advance Rare Disease and Hereditary Cancer Research and Support Diagnostics"},"content":{"rendered":"
\n

\nCombining expertise to advance precision medicine, while enabling efficient and timely <\/i>insights into the <\/i>diagnosis of rare diseases and hereditary cancer around the world<\/i>\n<\/p>\n

SOUTH SAN FRANCISCO, Calif. & CAMBRIDGE, Mass. & ROSTOCK, Germany & BERLIN–(BUSINESS WIRE)–Twist Bioscience Corporation<\/a> (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Centogene N.V.<\/a> (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced the launch of three next-generation sequencing (NGS) target enrichment panels to support rare disease and hereditary cancer research and support diagnostics.\n<\/p>\n

<\/a><\/p>\n

\nTarget enrichment panels enable more in-depth sequencing on target genes, reducing the need for comprehensive sequencing. This allows for more sensitive detection of target genetic sequences and provides higher confidence that variants will be detected, further driving the understanding of diseases and supporting healthcare professionals in providing precision medicine.\n<\/p>\n

\nLabs and research institutions can purchase these ready-made panels to help accelerate their research, and also have the option of using CENTOGENE\u2019s CentoCloud\u00ae<\/a> for the identification, prioritization, and classification of human genetic variants to expedite diagnostic analysis.\n<\/p>\n

\n\u201cThere are over 7,000 rare diseases impacting over 350 million patients, many of whom are not diagnosed until the late stages of the disease. Our mission is to provide data-driven, life-changing answers as early as possible to ultimately accelerate the development of treatments,\u201d said Kim Stratton, Chief Executive Officer at CENTOGENE. \u201cBy partnering with Twist to develop these custom panels, we are enabling access to diagnostics and generating novel insights for the medical community, fueled by multidimensional data from the CENTOGENE Biodatabank.\u201d\n<\/p>\n

\nAll three new Alliance Panels are highly curated using the CENTOGENE Biodatabank, with nearly 700,000 patients represented from over 120 highly diverse countries, over 70% of whom are of non-European descent. Identified sequences are then synthesized by Twist as biotinylated capture probes which are compatible with Twist\u2019s library preparation solution and target enrichment workflows. The panels offered through Twist will include:\n<\/p>\n